They are a type of investment with a return in the form of earned interest and are safer and less risky than other types of investments
Turner (2004)
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
As of the time of writing, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)
Practical takeaways (what to ask your doctor) My GLP1 medication causes nausea
Through my weight loss experience, Im hoping to gain long-lasting results that I can maintain even after I get off the GLP-1, one shared